Skip to main navigation Skip to main content

CMH : Clinical and Molecular Hepatology

OPEN ACCESS
ABOUT
BROWSE ARTICLES
FOR CONTRIBUTORS

Page Path

4
results for

"Il Han Song"

Article category

Keywords

Publication year

"Il Han Song"

Original Articles

Viral hepatitis

Efficacy and safety of sofosbuvir plus ribavirin for Korean patients with hepatitis C virus genotype 2 infection: A retrospective multi-institutional study
Young Min Kim, Suk Bae Kim, Il Han Song, Sae Hwan Lee, Hong Soo Kim, Tae Hee Lee, Young Woo Kang, Seok Hyun Kim, Byung Seok Lee, Hee Bok Chae, Myeong Jun Song, Ji Woong Jang, Soon Young Ko, Jae Dong Lee
Clin Mol Hepatol 2018;24(3):311-318.
Published online June 4, 2018
DOI: https://doi.org/10.3350/cmh.2017.0070
Background/Aims
Sofosbuvir plus ribavirin is a standard treatment for patients infected with chronic hepatitis C virus (HCV) genotype 2 in Korea. The purpose of this study was to examine the efficacy and safety of this treatment in Korean patients with chronic HCV genotype 2 infection.
Methods
We retrospectively analyzed clinical data of patients treated with sofosbuvir plus ribavirin for chronic HCV genotype 2 from May 2016 to December 2017 at eight hospitals located in the Daejeon-Chungcheong area.
Results
A total of 172 patients were treated with sofosbuvir plus ribavirin. Of them, 163 patients completed the treatment, and 162 patients were tested for sustained virologic response 12 weeks after treatment discontinuation (SVR12). Mean age was 59.6±12.3 years (27–96), and 105 (64.4%) patients were female. Of the total patients, 49 (30.1%) were diagnosed with cirrhosis, and 31 of them were treated for 16 weeks. Sofosbuvir plus ribavirin was the first-line treatment for 144 (88.3%) patients. Eleven (6.7%) patients were intolerant to previous interferon-based treatment. Eight (5.0%) patients relapsed after interferon-based treatment. HCV RNA non-detection rate at 4, 8, and 12 weeks was 97.5%, 99.1%, and 99.3%, respectively, and SVR12 was 98.8% (161/163). During treatment, 18 (11.0%) patients had to reduce their administrated dose of ribavirin because of anemia. One patient stopped the treatment because of severe anemia. Other adverse events, including dizziness, indigestion, and headache, were found in 26 (16.0%) patients.
Conclusions
A 12-16 week treatment with sofosbuvir plus ribavirin is remarkably effective and well tolerated in Korean patients with chronic HCV genotype 2 infection.

Citations

Citations to this article as recorded by  Crossref logo
  • Combination treatment with sofosbuvir and ribavirin for patients diagnosed with hepatitis C genotype 2: A real-world, single-center study
    Ik Sung Choi, Kwang Min Kim, Sang Goon Shim
    Arab Journal of Gastroenterology.2021; 22(1): 23.     CrossRef
  • Real-Life Effectiveness and Safety of Glecaprevir/Pibrentasvir for Korean Patients with Chronic Hepatitis C at a Single Institution
    Young Joo Park, Hyun Young Woo, Jeong Heo, Sang Gyu Park, Young Mi Hong, Ki Tae Yoon, Dong Uk Kim, Gwang Ha Kim, Hyung Hoi Kim, Geun Am Song, Mong Cho
    Gut and Liver.2021; 15(3): 440.     CrossRef
  • Sofosbuvir‐based therapies in genotype 2 hepatitis C virus cirrhosis: A real‐life experience with focus on ribavirin dose
    Carlo Smirne, Antonio D'Avolio, Mattia Bellan, Alessandro Gualerzi, Maria G. Crobu, Mario Pirisi
    Pharmacology Research & Perspectives.2021;[Epub]     CrossRef
  • Novel variant in glycophorin c gene protects against ribavirin-induced anemia during chronic hepatitis C treatment
    Jennifer J. Lin, Catrina M. Loucks, Jessica N. Trueman, Britt I. Drögemöller, Galen E.B. Wright, Eric M. Yoshida, Jo-Ann Ford, Samuel S. Lee, Richard B. Kim, Bandar Al-Judaibi, Ute I. Schwarz, Alnoor Ramji, Edward Tam, Colin J. Ross, Bruce C. Carleton
    Biomedicine & Pharmacotherapy.2021; 143: 112195.     CrossRef
  • Incidence, risk factors and impact on virological response of anemia in chronic genotype 2 hepatitis C receiving sofosbuvir plus ribavirin
    Chi-Ching Chen, Shui-Yi Tung, Kuo-Liang Wei, Chien-Heng Shen, Te-Sheng Chang, Wei-Ming Chen, Huang-Wei Xu, Chih-Wei Yen, Yi-Hsing Chen, Sheng-Nan Lu, Chao-Hung Hung
    Journal of the Formosan Medical Association.2020; 119(1): 532.     CrossRef
  • Hepatocellular Carcinoma Risk According to Regimens for Eradication of Hepatitis C Virus; Interferon or Direct Acting Antivirals
    Hye Won Lee, Dai Hoon Han, Hye Jung Shin, Jae Seung Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim
    Cancers.2020; 12(11): 3414.     CrossRef
  • Real-Life Effectiveness and Safety of Sofosbuvir-Based Therapy in Genotype 2 Chronic Hepatitis C Patients in South Korea, with Emphasis on the Ribavirin Dose
    Eun Sun Jang, Kyung-Ah Kim, Young Seok Kim, In Hee Kim, Byung Seok Lee, Youn Jae Lee, Woo Jin Chung, Sook-Hyang Jeong
    Gut and Liver.2020; 14(6): 775.     CrossRef
  • Direct-acting antivirals in East Asian hepatitis C patients: real-world experience from the REAL-C Consortium
    Chung-Feng Huang, Etsuko Iio, Dae Won Jun, Eiichi Ogawa, Hidenori Toyoda, Yao-Chun Hsu, Hiroaki Haga, Shinji Iwane, Masaru Enomoto, Dong Hyun Lee, Grace Wong, Chen-Hua Liu, Toshifumi Tada, Wan-Long Chuang, Ramsey Cheung, Jun Hayashi, Cheng-Hao Tseng, Sato
    Hepatology International.2019; 13(5): 587.     CrossRef
  • Comparison of the Clinical Characteristics and Outcomes between Leprosy-Affected Persons in Sorokdo and the General Population Affected by Chronic Hepatitis C in Korea
    Young-Hwan Ahn, Hyungcheol Park, Myeon Jae Lee, Dong Hyun Kim, Sung Bum Cho, Eunae Cho, Chung Hwan Jun, Sung Kyu Choi
    Gut and Liver.2019; 13(5): 549.     CrossRef
  • Does the old-fashioned sofosbuvir plus ribavirin treatment in genotype 2 chronic hepatitis C patients still works for Koreans?
    Jong Eun Yeon
    Clinical and Molecular Hepatology.2018; 24(3): 294.     CrossRef
  • Ribavirin/sofosbuvir

    Reactions Weekly.2018; 1727(1): 247.     CrossRef
  • 11,161 View
  • 206 Download
  • 11 Web of Science
  • Crossref

Viral hepatitis

Efficacy and safety of daclatasvir plus asunaprevir for Korean patients with HCV genotype Ib infection: a retrospective multi-institutional study
Byeong Wook Cho, Seok Bae Kim, Il Han Song, Sae Hwan Lee, Hong Soo Kim, Tae Hee Lee, Young Woo Kang, Seok Hyun Kim, Byung Seok Lee, Hee Bok Chae
Clin Mol Hepatol 2017;23(1):51-56.
Published online March 16, 2017
DOI: https://doi.org/10.3350/cmh.2016.0053
Background/Aims
The combination of daclatasvir (DCV) and asunaprevir (ASV) has demonstrated a high sustained virologic response at 12 weeks (SVR12) and a low rate of adverse events in previous clinical studies. The purpose of this study was to clarify the results of treatment and side effects in Korean patients with chronic hepatitis C virus (HCV) genotype Ib infection.
Methods
We retrospectively analyzed clinical data from chronic HCV genotype Ib patients treated with DCV+ASV from August 2015 to September 2016 at five hospitals in the Daejeon-Chungcheong area.
Results
A total of 152 patients were examined for resistance associated variants (RAVs). Among them, 15 (9.9%) were positive for Y93 and one (0.7%) was positive for L31. Of 126 patients treated with DCV+ASV, 83 patients completed treatment and 76 patients were included in safety and efficacy analysis. Five (6.6%) were positive for Y93 and 12 (15.8%) exhibited cirrhotic change. DCV+ASV was the first-line treatment for 58 (76.3%) patients. Eleven (14.5%) patients relapsed after previous treatment that included interferon and seven (9.2%) of these patients were found to be intolerant of interferon. Adverse events occurred in 10 (13.2%) patients and two patients stopped the medication because of severe itching and skin rash. SVR12 was 89.5% (68/76) in all patients and 91.5% (65/71) in RAV-negative patients.
Conclusions
DCV+ASV showed good efficacy in patients with HCV Ib infection in Korea. Close monitoring is needed for severe adverse events and treatment failure, which were uncommon.

Citations

Citations to this article as recorded by  Crossref logo
  • The Incidence and Care Cascade of the Hepatitis C Virus in Korea
    Young Eun Chon, Aejeong Jo, Eileen L. Yoon, Jonghyun Lee, Ho Gyun Shin, Min Jung Ko, Dae Won Jun
    Gut and Liver.2023; 17(6): 926.     CrossRef
  • Effect of direct-acting antivirals for hepatitis C virus-related hepatocellular carcinoma recurrence and death after curative treatment
    Young-Hwan Ahn, Heirim Lee, Ji Eun Han, Hyo Jung Cho, Jae Youn Cheong, Bumhee Park, Soon Sun Kim
    Journal of Liver Cancer.2022; 22(2): 125.     CrossRef
  • Clinical outcomes after the introduction of direct antiviral agents for patients infected with genotype 1b hepatitis C virus depending on the regimens: A multicenter study in Korea
    Jung Hyun Kwon, Sun Hong Yoo, Soon Woo Nam, Hee Yeon Kim, Chang Wook Kim, Chan Ran You, Sang Wook Choi, Se Hyun Cho, Joon‐Yeol Han, Do Seon Song, U Im Chang, Jin Mo Yang, Sung Won Lee, Hae Lim Lee, Nam Ik Han, Seok‐Hwan Kim, Myeong Jun Song, Pil Soo Sung,
    Journal of Medical Virology.2019; 91(6): 1104.     CrossRef
  • Discussion on critical points for a tailored therapy to cure hepatitis C virus infection
    Nadia Marascio, Angela Quirino, Giorgio Settimo Barreca, Luisa Galati, Chiara Costa, Vincenzo Pisani, Maria Mazzitelli, Giovanni Matera, Maria Carla Liberto, Alfredo Focà, Carlo Torti
    Clinical and Molecular Hepatology.2019; 25(1): 30.     CrossRef
  • Efficacy and Safety of Daclatasvir and Asunaprevir in Patients with Hepatitis C Virus Genotype 1b Infection on Hemodialysis
    Byung Seok Lee, Myeong Jun Song, Jung Hyun Kwon, Tae Hee Lee, Ji Woong Jang, Seok Hyun Kim, Sae Hwan Lee, Hong Soo Kim, Ji Hoon Kim, Seok Bae Kim, Soon Young Ko, Do Seon Song
    Gut and Liver.2019; 13(2): 191.     CrossRef
  • Daclatasvir and asunaprevir combination therapy for patients with chronic hepatitis C virus genotype 1b infection in real world
    Jae Young Oh, Byung Seok Kim, Chang Hyeong Lee, Jeong Eun Song, Heon Ju Lee, Jung Gil Park, Jae Seok Hwang, Woo Jin Chung, Byoung Kuk Jang, Young Oh Kweon, Won Young Tak, Soo Young Park, Se Young Jang, Jeong Ill Suh, Sang Gyu Kwak
    The Korean Journal of Internal Medicine.2019; 34(4): 794.     CrossRef
  • Real‐life effectiveness and safety of the daclatasvir/asunaprevir combination therapy for genotype 1b chronic hepatitis C patients: An emphasis on the pretreatment NS5A resistance‐associated substitution test
    Eun Sun Jang, Kyung‐Ah Kim, Young Seok Kim, In Hee Kim, Byung Seok Lee, Youn Jae Lee, Woo Jin Chung, Sook‐Hyang Jeong
    Journal of Medical Virology.2019; 91(12): 2158.     CrossRef
  • An integrated analysis of elbasvir/grazoprevir in Korean patients with hepatitis C virus genotype 1b infection
    Youn Jae Lee, Jeong Heo, Do Young Kim, Woo Jin Chung, Won Young Tak, Yoon Jun Kim, Seung Woon Paik, Eungeol Sim, Susila Kulasingam, Rohit Talwani, Barbara Haber, Peggy Hwang
    Clinical and Molecular Hepatology.2019; 25(4): 400.     CrossRef
  • Systematic review with meta‐analysis: effectiveness and tolerability of interferon‐free direct‐acting antiviral regimens for chronic hepatitis C genotype 1 in routine clinical practice in Asia
    F. Ji, B. Wei, Y. H. Yeo, E. Ogawa, B. Zou, C. D. Stave, Z. Li, S. Dang, N. Furusyo, R. C. Cheung, M. H. Nguyen
    Alimentary Pharmacology & Therapeutics.2018; 47(5): 550.     CrossRef
  • Early development of de novo hepatocellular carcinoma after direct‐acting agent therapy: Comparison with pegylated interferon‐based therapy in chronic hepatitis C patients
    S. H. Yoo, J. H. Kwon, S. W. Nam, H. Y. Kim, C. W. Kim, C. R. You, S. W. Choi, S. H. Cho, J.‐Y. Han, D. S. Song, U. I. Chang, J. M. Yang, H. L. Lee, S. W. Lee, N. I. Han, S.‐H. Kim, M. J. Song, S. Hwang, P. S. Sung, J. W. Jang, S. H. Bae, J. Y. Choi, S. K
    Journal of Viral Hepatitis.2018; 25(10): 1189.     CrossRef
  • Daclatasvir Plus Asunaprevir for the Treatment of Patients with Hepatitis C Virus Genotype 1b Infection: Real-World Efficacy, Changes in Liver Stiffness and Fibrosis Markers, and Safety
    Hye Won Lee, Se Rim Oh, Dong Yun Kim, Yechan Jeong, Seungtaek Kim, Beom Kyung Kim, Seung Up Kim, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Jun Yong Park
    Gut and Liver.2018; 12(3): 324.     CrossRef
  • Interaction of immunosuppressants with HCV antivirals daclatasvir and asunaprevir: combined effects with mycophenolic acid
    Petra E de Ruiter, Yashna Gadjradj, Robert J de Knegt, Herold J Metselaar, Jan NM Ijzermans, Luc JW van der Laan
    World Journal of Transplantation.2018; 8(5): 156.     CrossRef
  • Asunaprevir/daclatasvir

    Reactions Weekly.2017; 1653(1): 56.     CrossRef
  • Global elimination of hepatitis C virus infection: Progresses and the remaining challenges
    Reza Taherkhani, Fatemeh Farshadpour
    World Journal of Hepatology.2017; 9(33): 1239.     CrossRef
  • 10,974 View
  • 215 Download
  • 12 Web of Science
  • Crossref
Analysis of prognostic factors and 5-year survival rate in patients with hepatocellular carcinoma: a single-center experience
Sang Seok Lee, Hyun Sung Shin, Hyung Joon Kim, Su Jin Lee, Hyun Suk Lee, Kyung Hee Hyun, Yong Hyun Kim, Byoung Woon Kwon, Jin Hyung Han, Hoon Choi, Bae Hwan Kim, Joon Hyuk Lee, Ha Yan Kang, Hyun Deok Shin, Il Han Song
Korean J Hepatol 2012;18(1):48-55.
Published online March 22, 2012
DOI: https://doi.org/10.3350/kjhep.2012.18.1.48
Background/Aims

Hepatocellular carcinoma (HCC), which is the third most common cancer in Korea, has a very poor prognosis. However, only a few studies have performed a comprehensive survival-related analysis in all patients who were consecutively diagnosed and treated over a given period of time. The aim of this study was to determine the 5-year survival rate and its prognostic factors among HCC patients.

Methods

In total, 257 patients who were consecutively diagnosed with HCC between January 2000 and December 2003 were followed until death or until December 2008. We analyzed their survival outcomes according to their clinical characteristics, tumor staging, and treatment modalities, and determined the independent prognostic factors affecting survival.

Results

The patients were aged 59±10 years (mean±SD). During the follow-up period, 223 patients (86.8%) died and the overall median survival was 10.8 months; the 1-, 3-, and 5-year survival rates were 44.4%, 21.0%, and 12.1%, respectively. The outcomes in patients with tumor node metastasis (TNM) stage I or II and Child-Pugh class A or B were significantly better with surgical resection than with other treatment modalities (P<0.01). Patients who underwent supplementary transcatheter arterial chemoembolization as a second-line treatment after surgical resection had better outcomes than those who underwent surgical resection alone (P=0.02). Initial symptoms, Child-Pugh class, serum alpha-fetoprotein, tumor size, portal vein thrombosis, and TNM stage were found to be independent prognostic factors for survival among HCC patients.

Conclusions

This retrospective cohort study elucidated survival outcomes and prognostic factors affecting survival in HCC patients at a single center.

Citations

Citations to this article as recorded by  Crossref logo
  • Deciphering the influence of AP1M2 in modulating hepatocellular carcinoma growth and Mobility through JNK/ErK signaling pathway control
    Huan Wang, Xin Xie, Minwei Du, Xintong Wang, Kunyuan Wang, Xingyuan Chen, Hui Yang
    Gene.2025; 933: 148955.     CrossRef
  • Risk Factor Analysis of Death in Patients With Hepatic Cellular Carcinoma After Radical Operation: A Consecutive Cohort of 433 Patients
    Zhengyang He, Wenfeng Lu, Dongze Qiu, Weimin She
    Health Science Reports.2025;[Epub]     CrossRef
  • Insulin-Like Growth Factor 1 Receptor Drives Hepatocellular Carcinoma Growth and Invasion by Activating Stat3-Midkine-Stat3 Loop
    Caiqun Bie, Yanfang Chen, Huijun Tang, Qing Li, Lu Zhong, Xiaojuan Peng, Ying Shi, Junqin Lin, Junlong Lai, Shenglan Wu, Shaohui Tang
    Digestive Diseases and Sciences.2022; 67(2): 569.     CrossRef
  • Hepatocellular Carcinoma (HCC) in North-Western India: A Retrospective Study Focusing on Epidemiology, Risk Factors, and Survival
    Sweta Soni, Puneet Pareek, Satya narayan, Amrita Rakesh, Abhilasha Abhilasha
    Journal of Gastrointestinal Cancer.2022; 53(4): 921.     CrossRef
  • Zingerone suppresses proliferation, invasion, and migration of hepatocellular carcinoma cells by the inhibition of MTDH-mediated PI3K/Akt pathway
    Jian Fang, Huifen Zhu, Pengcheng Xu, Renya Jiang
    Journal of Receptors and Signal Transduction.2022; 42(4): 409.     CrossRef
  • Comprehensive Analysis of Prognostic Value and Immune Infiltration of the NT5DC Family in Hepatocellular Carcinoma
    Rongqi Li, Rongqiang Liu, Shiyang Zheng, Wenbin Liu, Hui Li, Dewei Li, Alessandro Granito
    Journal of Oncology.2022; 2022: 1.     CrossRef
  • Integrated Analysis Revealing the Senescence-Mediated Immune Heterogeneity of HCC and Construction of a Prognostic Model Based on Senescence-Related Non-Coding RNA Network
    Yanan Jiang, Kunpeng Luo, Jincheng Xu, Xiuyun Shen, Yang Gao, Wenqi Fu, Xuesong Zhang, Hongguang Wang, Bing Liu
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Cross-Linked Multimeric Pro-Peptides of Type III Collagen (PC3X) in Hepatocellular Carcinoma – A Biomarker That Provides Additional Prognostic Value in AFP Positive Patients


    Christina Jensen, Signe Holm Nielsen, Mohammed Eslam, Federica Genovese, Mette Juul Nielsen, Roslyn Vongsuvanh, Raj Uchila, David van der Poorten, Jacob George, Morten Asser Karsdal, Diana Julie Leeming, Nicholas Willumsen
    Journal of Hepatocellular Carcinoma.2020; Volume 7: 301.     CrossRef
  • Clinical characteristics and prognosis of 2887 patients with hepatocellular carcinoma
    Chun-yan Wang, Shengmian Li
    Medicine.2019; 98(4): e14070.     CrossRef
  • Analyses of a Panel of Transcripts Identified From a Small Sample Size and Construction of RNA Networks in Hepatocellular Carcinoma
    Zhiyong Sheng, Xiaolin Wang, Geliang Xu, Ge Shan, Liang Chen
    Frontiers in Genetics.2019;[Epub]     CrossRef
  • Validation of modified albumin-bilirubin-TNM score as a prognostic model to evaluate patients with hepatocellular carcinoma
    Omar Elshaarawy, Alzhraa Alkhatib, Mostafa Elhelbawy, Asmaa Gomaa, Naglaa Allam, Ayman Alsebaey, Eman Rewisha, Imam Waked
    World Journal of Hepatology.2019; 11(6): 542.     CrossRef
  • A new prognostic score can predict survival after hepatocellular carcinoma treatment in a cohort of 1302 Egyptian hepatocellular carcinoma patients
    Ashraf O. Abdelaziz, Hend I. Shousha, Ahmed H. Abdelmaksoud, Yasmin Saad, Tamer M. Elbaz, Zeinab A. Soliman, Ayman Salah, Rania Lithy, Mona Ahmed, Mohamed M. Nabil
    European Journal of Gastroenterology & Hepatology.2018; 30(5): 514.     CrossRef
  • The SMYD3 VNTR 3/3 polymorphism confers an increased risk and poor prognosis of hepatocellular carcinoma in a Chinese population
    Rui-Dong Li, Yan-Hua Tang, Hui-Li Wang, Dong Yang, Li-Jun Sun, Wei Li
    Pathology - Research and Practice.2018; 214(5): 625.     CrossRef
  • Somatostatin receptors in resected hepatocellular carcinoma: status and correlation with markers of poor prognosis
    Marie Lequoy, Christèle Desbois‐Mouthon, Dominique Wendum, Vandana Gupta, Jean‐Luc Blachon, Olivier Scatton, Sylvie Dumont, Mireille Bonnemaire, Fabien Schmidlin, Olivier Rosmorduc, Laetitia Fartoux
    Histopathology.2017; 70(3): 492.     CrossRef
  • Fibro markers for prediction of hepatocellular carcinoma in Egyptian patients with chronic liver disease
    Lamiaa Mobarak, Dalia Omran, Mohammed M. Nabeel, Zeinab Zakaria
    Journal of Medical Virology.2017; 89(6): 1062.     CrossRef
  • Prognostic Value of FDG Uptake of Portal Vein Tumor Thrombosis in Patients With Locally Advanced Hepatocellular Carcinoma
    Jeong Won Lee, Sang Hyun Hwang, Do Young Kim, Kwang-Hyub Han, Mijin Yun
    Clinical Nuclear Medicine.2017; 42(1): e35.     CrossRef
  • Anti-GPC3-CAR T Cells Suppress the Growth of Tumor Cells in Patient-Derived Xenografts of Hepatocellular Carcinoma
    Zhiwu Jiang, Xiaofeng Jiang, Suimin Chen, Yunxin Lai, Xinru Wei, Baiheng Li, Simiao Lin, Suna Wang, Qiting Wu, Qiubin Liang, Qifa Liu, Muyun Peng, Fenglei Yu, Jianyu Weng, Xin Du, Duanqing Pei, Pentao Liu, Yao Yao, Ping Xue, Peng Li
    Frontiers in Immunology.2017;[Epub]     CrossRef
  • Secreted phosphoprotein 24 kD (Spp24) inhibits growth of hepatocellular carcinoma in vivo
    Lifeng Lao, Jia Shen, Haijun Tian, Guibin Zhong, Samuel S. Murray, Jeffrey C. Wang
    Environmental Toxicology and Pharmacology.2017; 51: 51.     CrossRef
  • XRCC1 and XPD polymorphisms and their relation to the clinical course in hepatocarcinoma patients
    Qinghai Guan, Zhiqiang Chen, Qiangpu Chen, Xuting Zhi
    Oncology Letters.2017; 14(3): 2783.     CrossRef
  • Clinical effects of miR-101 on prognosis of hepatocellular carcinoma and carcinogenic mechanism of anti-miR-101
    Xuecheng Lv, Jinghua Li, Bingnan Yang
    Oncology Reports.2016; 36(4): 2184.     CrossRef
  • Importance of SALL4 in the development and prognosis of hepatocellular carcinoma
    Fei Yin, Xin Han, Shu-Kun Yao, Xiao-Ling Wang, Hui-Chai Yang
    World Journal of Gastroenterology.2016; 22(9): 2837.     CrossRef
  • Multipotent mesenchymal stromal cells: A promising strategy to manage alcoholic liver disease
    Fernando Ezquer
    World Journal of Gastroenterology.2016; 22(1): 24.     CrossRef
  • Mitochondrial DNA Copy Number in Egyptian Patients with Hepatitis C Virus-Related Hepatocellular Carcinoma
    Doaa I. Hashad, Amany S. Elyamany, Perihan E. Salem
    Genetic Testing and Molecular Biomarkers.2015; 19(11): 604.     CrossRef
  • Comparison of Transarterial Chemoembolization and Hepatic Resection for Large Solitary Hepatocellular Carcinoma: A Propensity Score Analysis
    Yun Bin Lee, Dong Hyeon Lee, Yuri Cho, Su Jong Yu, Jeong-Hoon Lee, Jung-Hwan Yoon, Hyo-Suk Lee, Hyo-Cheol Kim, Nam-Joon Yi, Kwang-Woong Lee, Kyung-Suk Suh, Jin Wook Chung, Yoon Jun Kim
    Journal of Vascular and Interventional Radiology.2015; 26(5): 651.     CrossRef
  • Vascular invasion in hepatitis B virus-related hepatocellular carcinoma with underlying cirrhosis: possible associations with ascites and hepatitis B viral factors?
    Chuan Chen, Dong-Ping Chen, Yan-Yan Gu, Liang-Hao Hu, Dan Wang, Jin-Huan Lin, Zhao-Shen Li, Jing Xu, Ge Wang
    Tumor Biology.2015; 36(8): 6255.     CrossRef
  • Prognostic Significance of Preoperative Serum Alpha-fetoprotein in Hepatocellular Carcinoma and Correlation with Clinicopathological Factors: a Single-center Experience from China
    Song-Lin An, Ting Xiao, Li-Ming Wang, Wei-Qi Rong, Fan Wu, Li Feng, Fa-Qiang Liu, Fei Tian, Jian-Xiong Wu
    Asian Pacific Journal of Cancer Prevention.2015; 16(10): 4421.     CrossRef
  • High circulating microRNA-122 expression is a poor prognostic marker in patients with hepatitis B virus-related hepatocellular carcinoma who undergo radiofrequency ablation
    Hyo Jung Cho, Jai Keun Kim, Ji Sun Nam, Hee Jung Wang, Jei Hee Lee, Bong Wan Kim, Soon Sun Kim, Choong Kyun Noh, Sung Jae Shin, Kee Myung Lee, Sung Won Cho, Jae Youn Cheong
    Clinical Biochemistry.2015; 48(16-17): 1073.     CrossRef
  • Impact of postoperative hepatitis B virus reactivation in hepatocellular carcinoma patients who formerly had naturally suppressed virus
    Jung Il Lee, Ja Kyung Kim, Hye Young Chang, Jin‐Woo Lee, Joon Mee Kim, Hyun Jung Chung, Young Soo Kim, Kwan Sik Lee
    Journal of Gastroenterology and Hepatology.2014; 29(5): 1019.     CrossRef
  • Assessing Prognostic Significance of Preoperative Alpha-Fetoprotein in Hepatitis B-Associated Hepatocellular Carcinoma: Normal is not the New Normal
    Sima Blank, Qin Wang, M. Isabel Fiel, Wei Luan, Ki Won Kim, Hena Kadri, John Mandeli, Spiros P. Hiotis
    Annals of Surgical Oncology.2014; 21(3): 986.     CrossRef
  • Histological improvement following administration of autologous bone marrow‐derived mesenchymal stem cells for alcoholic cirrhosis: a pilot study
    Yoon Ok Jang, Young Ju Kim, Soon Koo Baik, Moon Young Kim, Young Woo Eom, Mee Yon Cho, Hong Jun Park, So Yeon Park, Bo Ra Kim, Jae Woo Kim, Hyun Soo Kim, Sang Ok Kwon, Eun Hee Choi, Yong Man Kim
    Liver International.2014; 34(1): 33.     CrossRef
  • Effect of bone marrow-derived mesenchymal stem cells on hepatic fibrosis in a thioacetamide-induced cirrhotic rat model
    Yoon Ok Jang, Moon Young Kim, Mee Yon Cho, Soon Koo Baik, Youn Zoo Cho, Sang Ok Kwon
    BMC Gastroenterology.2014;[Epub]     CrossRef
  • Survival and Prognostic Factors for Hepatocellular Carcinoma: an Egyptian Multidisciplinary Clinic Experience
    Ashraf Omar Abdelaziz, Tamer Mahmoud Elbaz, Hend Ibrahim Shousha, Mostafa Mohamed Ibrahim, Mostafa Abdel Rahman El-Shazli, Ahmed Hosni Abdelmaksoud, Omar Abdel Aziz, Hisham Atef Zaki, Inas Anwar Elattar, Mohamed Mahmoud Nabeel
    Asian Pacific Journal of Cancer Prevention.2014; 15(9): 3915.     CrossRef
  • Lesson from 610 liver resections of hepatocellular carcinoma in a single center over 10 years
    Dai Hoon Han, Gi Hong Choi, Jun Yong Park, Sang Hoon Ahn, Kyung Sik Kim, Jin Sub Choi, Kwang-Hyub Han
    World Journal of Surgical Oncology.2014;[Epub]     CrossRef
  • Management of Hepatocellular Carcinoma: Updated Review
    Tamer Elbaz, Mohamed El Kassas, Gamal Esmat
    Journal of Cancer Therapy.2013; 04(02): 536.     CrossRef
  • 11,516 View
  • 56 Download
  • Crossref
Case Report
Ruptured duodenal varices arising from the main portal vein successfully treated with endoscopic injection sclerotherapy: a case report
Ha Yan Kang, Won Kyung Lee, Yong Hyun Kim, Byung Woon Kwon, Myung Soo Kang, Suk Bae Kim, Il Han Song
Korean J Hepatol 2011;17(2):152-156.
Published online June 23, 2011
DOI: https://doi.org/10.3350/kjhep.2011.17.2.152

Duodenal varices result from retroperitoneal portosystemic shunts that usually come from the pancreaticoduodenal vein and drain into the inferior vena cava. Because they are a rare but fatal cause of gastrointestinal bleeding, a prompt hemostatic intervention is mandatory. A 62-year-old man who had a history of excessive alcohol consumption presented with massive hematemesis and melena. Emergent endoscopy revealed ruptured varices with an adhering whitish fibrin clot on the postbulbar portion of the duodenum. Abdominal computed tomography demonstrated a cirrhotic liver with venous collaterals around the duodenum and extravasated contrast in the second and third portions. The collaterals originated from the main portal vein and drained via the right renal vein into the inferior vena cava. Endoscopic injection sclerotherapy with cyanoacrylate was successful in achieving hemostasis, and resulted in the near eradication of duodenal varices at a 6-month follow-up.

Citations

Citations to this article as recorded by  Crossref logo
  • New sights in ectopic varices in portal hypertension
    K He, K Pang, X Yan, Q Wang, D Wu
    QJM: An International Journal of Medicine.2024; 117(6): 397.     CrossRef
  • Duodenal Variceal Rupture during Atezolizumab and Bevacizumab Treatment for Hepatocellular Carcinoma
    Mio Tsuruoka, Jun Inoue, Keishi Ouchi, Kaname Uno, Hideaki Itami, Masashi Ninomiya, Tomoaki Iwata, Akitoshi Sano, Kosuke Sato, Masazumi Onuki, Satoko Sawahashi, Tomoyuki Koike, Atsushi Masamune
    Internal Medicine.2023; 62(10): 1467.     CrossRef
  • Small Intestine Varices in Cirrhosis at a High-Volume Liver Transplant Center: A Retrospective Database Study and Literature Review
    Claire L. Jansson-Knodell, Gerardo Calderon, Regina Weber, Marwan Ghabril
    American Journal of Gastroenterology.2021; 116(7): 1426.     CrossRef
  • Multidetector computed tomography three-dimensional and multiplanar reconstruction diagnosis of a rare cause of gastrointestinal bleeding: A case report
    Yong Cai, Xiao-Bo Chen, Da-Hai Mai, Ping Wu, Yong-Hai Chen, Hua Chen
    World Journal of Gastrointestinal Surgery.2021; 13(1): 87.     CrossRef
  • Effectiveness and safety of endoscopic treatment for duodenal variceal bleeding: a systematic review
    Wan Yipeng, Liu Cong, Wan Sizhe, Huang Chenkai, Wang Anjiang, Zhu Xuan
    European Journal of Gastroenterology & Hepatology.2021; 33(4): 461.     CrossRef
  • Small bowel bleeding
    Stefania Chetcuti Zammit, Reena Sidhu
    Current Opinion in Gastroenterology.2018; 34(3): 165.     CrossRef
  • A case report of bleeding from a duodenal varix: Rare cause of upper gastrointestinal bleeding
    Vincent Khor, Yuen Soon, Lwin Aung
    International Journal of Surgery Case Reports.2018; 49: 205.     CrossRef
  • Endoscopic Sclerotherapy with a Large Volume of High Concentration of Cyanoacrylate for Jejunal Variceal Bleeding bys Single-Balloon Enteroscopy
    Jyong-Hong Lee, Chih-Sheng Wu, Jen-Hsuan Huang
    Medicina.2018; 54(5): 68.     CrossRef
  • Duodenal variceal bleed: an unusual cause of upper gastrointestinal bleed and a difficult diagnosis to make
    Shradha Bhagani, Conchubhair Winters, Sulleman Moreea
    BMJ Case Reports.2017; 2017: bcr2016218669.     CrossRef
  • Complete Eradication of Bleeding Duodenal Varices with Endoscopic Polydocanol Sclerotherapy
    Safak Meric Ozgenel, Tuncer Temel,, Abdülvahhap Aktas, Aysegül Özakyol
    Euroasian Journal of Hepato-Gastroenterology.2016; 6(2): 176.     CrossRef
  • Endoscopic therapies for small-bowel bleeding
    Jennifer L. Maranki, Oleh Haluszka
    Techniques in Gastrointestinal Endoscopy.2012; 14(2): 106.     CrossRef
  • 8,269 View
  • 56 Download
  • Crossref